Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kinder Morgan Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Kinder Morgan Inc trades at $31.7 (market cap $70.10B). The key difference: Kinder Morgan Inc is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Kinder Morgan Inc pays a 3.75% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KMI | |
|---|---|---|
Market Cap | $29.60B | $70.10B |
Sector | Health | Energy |
52-Week High | $491.22 | $34.31 |
52-Week Low | $205.48 | $25.84 |
Enterprise Value | $27.56B | $102.15B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
KMI trades at $31.70, up 0.99% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates, and raised full-year guidance. Recent news highlights a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in natural gas infrastructure. Fundamentals show solid revenue growth, with 2025 revenue at $16.94 billion and net income margin improving to 19.31%.
The outlook is positive due to contracted cash flows and a robust project pipeline, but risks include high debt levels and exposure to energy market volatility. Analyst sentiment is mixed, with a near-even split between buy and hold ratings. The stock offers a dividend yield supported by stable cash generation, though valuation multiples like a P/E of 20.31 may limit near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
